Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Membrex + messenger RNA
- Development stage
- Unknown
- Lead developer
- Metaclipse Therapeutics
- Modality
- Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
Membrex + messenger RNA is a personalized prime-boost cancer immunotherapy being developed by Metaclipse Biopharma, specifically targeting nasopharyngeal carcinoma (NPC). The strategy utilizes the Membrex platform, which consists of autologous membrane vesicles derived from a patient's tumor tissue and modified with immunostimulatory proteins, as a priming agent. This is followed by a boost with an mRNA vaccine encoding specific tumor antigens to enhance and sustain tumor-specific immune responses. In September 2025, the program received an NCI SBIR Phase 1 Contract Award to support its preclinical development and transition toward clinical evaluation.
- Other names
- Membrex + mRNA vaccineMembrex (prime-boost mRNA combination)
02
Targets
pMHC-I (Peptide–MHC class I complex)CD28 (Cluster of Differentiation 28)PRR (Pattern recognition receptors)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on Membrex + messenger RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Membrex + messenger RNA.